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Our previous study demonstrated that administration of garlic-derived antioxidant S-allylmercaptocysteine (SAMC) ameliorated
hepatic injury in a nonalcoholic fatty liver disease (NAFLD) rat model. Our present study aimed to investigate the mechanism of
SAMC on NAFLD-induced hepatic apoptosis and autophagy. Adult female rats were fed with a high-fat diet for 8 weeks to develop
NAFLD with or without intraperitoneal injection of 200mg/kg SAMC for three times per week. During NAFLD development,
increased apoptotic cells and caspase-3 activation were observed in the liver. Increased apoptosis was modulated through both
intrinsic and extrinsic apoptotic pathways. NAFLD treatment also enhanced the expression of key autophagic markers in the liver
with reduced activity of LKB1/AMPK and PI3K/Akt pathways. Increased expression of proapoptotic regulator p53 and decreased
activity of antiautophagic regulator mTOR were also observed. Administration of SAMC reduced the number of apoptotic cells
through downregulation of both intrinsic and extrinsic apoptotic mechanisms. SAMC also counteracted the effects of NAFLD
on LKB1/AMPK and PI3K/Akt pathways. Treatment with SAMC further enhanced hepatic autophagy by regulating autophagic
markers and mTOR activity. In conclusion, administration of SAMC during NAFLD development in rats protects the liver from
chronic injury by reducing apoptosis and enhancing autophagy.
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is one of the
most common chronic liver diseases in Western countries.
It ranges from simple fatty liver (steatosis) to nonalcoholic
steatohepatitis (NASH) and even cirrhosis [1]. At present,
the pathogenesis of NAFLD is not fully understood. Key
events that contribute to the initiation and progression of
NAFLD are summarized in a “multi-hit” model [2, 3]. In this
model, dysregulated metabolism of free fatty acids (FFAs) is
considered as the “first-hit” of NAFLD pathogenesis, which
leads to insulin resistance and fat accumulation in the liver.
Inflammatory response, oxidative stress, apoptosis, and even
autophagy serve as “following-hits” that contribute to the
ongoing inflammation (NASH). Emerging data suggest that
apoptosis plays a critical role in NAFLD-induced liver injury
and in the progression from steatosis to NASH and cirrhosis
[4–6]. Moreover, the degree of apoptosis is closely associated
with the severity of NASH and the stage of fibrosis [7]. Thus,
inhibition of apoptosis in the liver may be a useful treatment
strategy of NAFLD.
There are two major apoptotic pathways: intrinsic (mito-
chondrial) and extrinsic (death receptor) pathways. Both
pathways are involved in the pathogenesis of NAFLD [8]. p53
is a transcription factor that controls the activation of both
intrinsic and extrinsic apoptotic pathways in response to a
variety of stimuli including direct DNA damage, oncogenes,
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hypoxia, and survival factor deprivation [9]. For intrin-
sic pathway, p53 enhances the expression of proapoptotic
genes, such as Bak1 and Bax, to facilitate the mitochondria-
mediated apoptosis. For extrinsic pathway, apart from the
signal transduction of death receptors (e.g., Fas and FADD)
on the cell membrane, p53 also activates caspase-8 in the
cytosol to promote the caspase signaling cascade [9, 10].
Othermembers of the Bcl-2 family, such as Bcl-2 and Bcl-XL,
antagonize the proapoptotic effects mediated by p53 to act as
an antiapoptosis mechanism [11]. However, the relationship
between the initiation of NAFLD and apoptosis is still poorly
understood.
Macroautophagy (hereafter referred to as autophagy)
refers to a process where cytoplasmic materials are
sequestered and degraded by lysosomal pathway. As a
terminal target of insulin signaling, mTOR negatively
controls the activity of ULK1 complex and then regulates
the autophagic sequestration via vps34 and beclin1. After
that, autophagosomes fuse with lysosome to degrade target
cytosolic contents through the action of Atg 5, 12, and LC3
[12]. In the liver, autophagy is believed to exert several
important physiological functions, including starvation
adaptation, quality control (to prevent the accumulation of
degenerating proteins and organelles), and prevention of
tumorigenesis [13]. However, the exact role of autophagy
during NAFLD progression remains largely unknown.
S-allylmercaptocysteine (SAMC) is a water-soluble com-
pound of aged garlic. It is a major in vivo metabolic
product of diallyl disulfide and allicin, the organo-sulfur
compounds of raw garlic [14]. SAMC has been characterized
for its anticancer property both in vivo and in vitro [15–
17]. In addition, SAMC also plays a preventive role in an
acetaminophen-induced acute liver injurymodel through the
inhibition of the activity of cytochrome P450 2E1 (CYP2E1)
[18]. We previously demonstrated the protective properties
of SAMC in both carbon tetrachloride-induced acute liver
injury model [19] and NAFLD-induced chronic liver injury
model [20]. In these studies, SAMC reduces the key events
that contribute to the hepatic damage including oxidative
stress, inflammation, and necrosis. However, whether the
application of SAMC could alleviate apoptosis in NAFLD
liver injury is still largely unknown. In the current study,
we investigated the antiapoptotic and autophagic enhancing
effects of SAMC in a NAFLD rat model. Signaling pathways
regulated by SAMC on hepatic apoptosis and autophagy have
also been characterized.
2. Materials and Methods
2.1. Reagents. SAMC pure powder was kindly given by Dr.
Patrick M. T. Ling (Queensland University of Technology,
Australia) and originally from Wakunaga Co. Ltd (Osaka,
Japan). The purity of the SAMC powder is more than 95%
by HPLC analysis. It does not contain any other garlic
compound such as SAC or allicin. SAMC was dissolved in a
phosphate buffered saline containing 10% L-dextrose and 1%
gum Arabic (w/v) at pH 4.5. Antibodies against Bcl-2, Bcl-
XL, Bak1, Bax, vps34, and phosphorylated phosphoinositide
3-kinase (PI3 K) p85𝛼 at Tyr508 were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies of
phosphorylated liver kinase B1 (LKB1) at Ser428, total LKB1,
phosphorylated AMP-activated protein kinase (AMPK) at
Thr172, total AMPK, phosphorylated p53 at Ser15, total p53,
phosphorylated Akt at Ser473, total Akt, total PI3 K (p85
subunit), cytochrome c, TNF-related apoptosis-inducing lig-
and (TRAIL), Fas, Fas-associated protein with death domain
(FADD), cleaved caspase-3, cleaved caspase-8, phosphory-
lated mTOR at Ser2448, mTOR, beclin 1, Atg12, LC3 II, and
p62 were from Cell Signaling Technology (Danvers, MA,
USA).
2.2. Animals and Treatments. Eight weeks healthy female
SD rats with body weight ranging from 180–200 g were
purchased from the Laboratory Animal Unit (LAU), The
University of Hong Kong. Rats were kept under standard
conditions for three days before starting of the experiment
with free access to animal chow and tap water. The animals
were divided into four groups (𝑛 = 7 in each group),
namely, (1) control group; (2) NAFLD group; (3) SAMC
treatment only group (200mg/kg in solvent, intraperitoneal
injection, three times per week); and (4) NAFLD and SAMC
cotreatment group. Pilot studies on hepatic histology and
serum ALT showed that this solvent had no hepatic toxicity.
The development of NAFLD in rats, including the recipe and
preparation protocols of diet, was performed based on our
previously described voluntary oral feeding NAFLD animal
model [18]. The optimum dosage of SAMC was previously
shown to be effective in protecting the liver from both acute
and chronic injury [19, 20]. Instead of oral administration
in a dietary supplement form, SAMC was intraperitoneally
injected to avoid possible degradation prior to absorption
through the gastrointestinal tract (GIT). After eight weeks,
the rats were euthanized by an overdose of anesthesia accord-
ing to the protocols approved by the Committee on the Use of
Live Animals in Teaching and Research at The University of
Hong Kong. The Laboratory Animal Unit of the University
of Hong Kong is fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
International (AAALAC international). Liver samples were
collected for further analysis.
2.3. Processing of Tissue and TUNEL Assay. Liver tissue
samples were fixed in 10% phosphate-buffered formalin pro-
cessed for histology and embedded in paraffin blocks. Five-
micrometer tissue sections were subjected to hematoxylin
and eosin (H&E) staining and terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling (TUNEL)
assay using an in situ cell death detection kit (Roche Diag-
nostics, Basel, Switzerland). After H&E staining, hepatic
injury was evaluated by using the NAFLD activity score
(NAS) system as previously described [20]. For TUNEL
assay, TUNEL-positive parenchymal and nonparenchymal
cell signals were quantified in terms of the intensity of the
red stain. This parameter is represented by the mean optical
density in ten random fields per section per animal using the
ImageJ software (NIH, Bethesda, MD, USA).
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2.4. Western Blot Analysis. Cytosolic protein of each liver
sample was extracted by using NE-PER protein extraction
system (Pierce Biotechnology, Rockford, IL, USA) with the
addition of Halt phosphatase inhibitor cocktail (Pierce).
Before Western blot, protein was diluted and mixed with 2×
sample buffer (0.1 M Tris-HCl, pH 6.8, 20% glycerol, 4%
sodium dodecyl sulfate, 0.2% Bromophenol Blue, 5.25% 𝛽-
mercaptoethanol). The mixture was denatured at 99∘C for
5 min and followed by electrophoresis in a 10% polyacry-
lamide gel. The protein was then transferred to an Immun-
Blot PVDF Membrane (Bio-Rad) in a TE series transfer
electrophoresis unit (Hoefer Inc., Holliston, MA, USA). The
membrane was then incubated in blocking buffer (5% nonfat
milk powder in TBST, 100 mM Tris-HCl, pH 7.5, 0.9% NaCl,
0.1% Tween 20) for 1 hour followed by incubation with
appropriate primary antibodies in TBST overnight at 4∘C
with gentle agitation. On the following day, the membrane
was washed with TBST and incubated with appropriate
secondary antibodies for 2 h at room temperature. Beta-
actin was used as the internal control. After washing off
the unbound antibody with TBST, the expression of the
antibody-linked protein was determined by an ECL Western
Blotting Detection Reagents (GE Healthcare). The optical
density of the bands was measured and quantified by ImageJ
software (National Institute of Health, MD). The ratio of the
optical density of the protein product to the internal control
was calculated and was expressed as a percentage of the
control expression by ImageJ.
2.5. Statistical Analysis. Data from each group were
expressed as means ± SEM. Statistical comparison between
groups was done using the Kruskal-Wallis test followed by
Dunn’s post hoc test to compare all groups. A P < 0.05 was
considered to be statistically significant (Prism 5.0, Graphpad
software, Inc., San Diego, CA, USA).
3. Results
3.1. SAMC Cotreatment Improved Hepatic Histology during
NAFLD Development. Eight-week induction of NAFLD by
high-fat diet induced showed increase in lipid accumulation
and inflammatory foci deposition in the rat liver. SAMC
cotreatment significantly improved the hepatic histology by
reducing the fatty droplets and inflammatory foci number
without influencing the healthy rats (Figures 1(a)–1(d)).
NAS quantification of liver sections further confirmed the
beneficial effects of SAMC cotreatment on hepatic histology
(Figure 1(e)).
3.2. Addition of SAMC Reduced Apoptosis in the Liver during
NAFLD Development. After 8 weeks of NAFLD induction
using high-fat diet, hepatic apoptosis in NAFLD rats was
more evident than that in other three groups (∼3.5-fold),
as shown by the quantification of TUNEL assay staining
(Figure 2(e)). Cotreatment with 200mg/kg SAMC signifi-
cantly reduced the intensity of hepatic apoptotic positive
signal comparable to the control level in the liver section
(Figures 2(a)–2(d)). Vehicle-treated SAMC group rats did
not show increase in the intensity of apoptotic signals
when compared with the control group (Figure 2(c)). As the
central apoptotic signaling pathway, caspase-3 is activated
under the signals from both intrinsic and extrinsic apoptotic
pathways [21]. In NAFLD rats, the expression level of cleaved
(activated) caspase-3 was markedly higher than the control
level (∼7.2-fold), which was consistent with the TUNEL assay.
Addition of SAMC significantly and markedly reduced the
level of the activated caspase-3 induced by a high-fat diet
(Figure 2(f)).
3.3. Intrinsic Apoptotic Signaling Pathway Components
Involved in SAMC Attenuation. In NAFLD rats, the protein
level of phosphorylated p53 was highly elevated, indicating
an activation of the master regulator of cellular apoptosis.
Cotreatment with SAMC during NAFLD development
significantly reduced the phosphorylated p53 expression to
the control level without significantly disturbing its baseline
and the total form of p53 expressions (Figure 3(a)). As an
important intrinsic intermediate in apoptosis, the protein
level of cytochrome c was also upregulated in NAFLD rats
but attenuated in SAMC cotreatment rats (Figure 3(b)). The
antiapoptotic members of the Bcl-2 family (Bcl-2 and Bcl-
XL) showed inhibited expression during the development of
NAFLD, while the level of proapoptotic members (Bak1 and
Bax) was upregulated (Figures 3(c)–3(f)). Administration
of SAMC potently counter-acted the effects of NAFLD on
these Bcl-2 family members through the intrinsic apoptotic
pathway.
3.4. Extrinsic Apoptotic Signaling Pathways Components
Involved in SAMC Attenuation. To further examine the
effects of NAFLD and SAMC on the extrinsic apoptotic
pathway, protein expressions of key extrinsic apoptotic path-
way components, including Fas, TRAIL, FADD, and cleaved
caspase-8, were measured by Western blot. The expression
level of Fas, TRAIL, FADD, and cleaved caspase-8 was
upregulated during the NAFLD progression by 7.1-fold, 2.0-
fold, 3.2-fold, and 1.7-fold, respectively. Administration of
SAMC significantly reduced the elevated expressions of these
proteins comparable to the control levels (Figures 4(a)–4(d)).
SAMC treatment alone did not influence the basal expression
of TRAIL and cleaved caspase-8 but increased basal Fas level
and decreased basal FADD level.
3.5. SAMC Alleviated Hepatic Apoptosis through Targeting
LKB1/AMPK and PI3 K/Akt Pathways. To explore the signal-
ing pathways involved in SAMC attenuated apoptosis, we
measured the phosphorylation and total forms of key com-
ponents from two kinase pathways, namely, LKB1/AMPK
and PI3K/Akt signaling pathways. Development of NAFLD
in rats inhibited the phosphorylation of LKB1, AMPK,
PI3 K, and Akt proteins (Figures 5(a)–5(d)). The influence
of NAFLD on total LKB1, AMPK, and Akt was not obvious,
while total PI3 K expression was inhibited by NAFLD. Addi-
tion of SAMC dramatically restored the phosphorylation
form of LKB1 and Akt to levels that were higher than control
(Figures 5(a) and 5(d)). Treatment of SAMC also upregulated
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Figure 1: Cotreatment with SAMC during NAFLD development improved hepatic histology in rats. ((a)–(d)) Representative images of H&E
staining in the rat liver sections ((a) control, (b) NAFLD, (c) SAMC, (d) NAFLD + SAMC) and (e) quantitative data of NAS score of H&E
staining. Data presented are expressed as Mean ± SEM (𝑛 = 7) and experimental groups marked by different letters represented significant
differences between groups at 𝑃 < 0.05 (Kruskal-Wallis test followed by Dunn’s post hoc test). Magnification: 200x. Bar: 20 microns. N + S:
NAFLD + SAMC cotreatment.
the phosphorylated and total protein expressions of PI3 K
when compared with the NAFLD group (Figure 5(c)). For
phosphorylated AMPK, SAMC also slightly restored its level
when compared with the NAFLD rat level, although the
change was not statistically significant (Figure 5(b)).
3.6. SAMC Treatment Further Enhanced Autophagy through
Inhibition of mTOR Activity. NAFLD rats showed increased
expression level of autophagic markers during NAFLD pro-
gression, including vps34, beclin 1, Atg 12, and LC3 II,
with inhibited phosphorylation level of autophagic inhibitor
mTOR (Figures 6(a)–6(e)). Interestingly, cotreatment with
SAMC further enhanced the expression level of vps34, beclin
1, Atg 12, and LC3 II. It also further decreased the phospho-
rylation of mTOR, indicating a further induction of hepatic
autophagy after NAFLD progression through inhibition of
mTOR activity (Figures 6(a)–6(e)). As an ubiquitin binding
protein for autophagy, the protein expression of p62 was
downregulated in the NAFLD group and further reduced by
the cotreatment of SAMC (Figure 6(f)).
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Figure 2: Addition of SAMC during the development of NAFLD reduced the hepatic apoptosis in rats. ((a)–(d)) Representative results of
TUNEL assay in the rat liver sections by fast red staining ((a) control, (b) NAFLD, (c) SAMC, (d) NAFLD+SAMC) and (e) quantitative data
of TUNEL assay results (a.u. = arbitrary unit). (f) Protein expression of cleaved (activated) caspase-3 was measured byWestern blot and then
quantified by ImageJ software. Data presented are expressed as mean ± SEM (𝑛 = 7), and experimental groups marked by different letters
represented significant differences between groups at 𝑃 < 0.05 (Kruskal-Wallis test followed by Dunn’s post hoc test). Magnification: 200x.
Bar: 20 microns. N + S: NAFLD + SAMC cotreatment.
4. Discussion
Despite the huge effort put in the prevention and treatment
of NAFLD from researchers and clinicians, there are few
options to retard or even reverse the progression of this
disease. As to date, weight loss is the most recognized ther-
apeutic method to improve liver injury induced by NAFLD
[22]. Recently, several drugs have been assessed for the
treatment of NAFLD, including antiobesity regimens, insulin
sensitizers, antihyperlipidemics, and antioxidants. However,
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Figure 3: Addition of SAMC attenuated intrinsic apoptotic pathway components through p53 during the development of NAFLD. Protein
expressions of (a) phosphorylated and total p53, (b) cytochrome c, (c) Bcl-2, (d) Bcl-XL, (e) Bak1, and (f) Bax were measured byWestern blot
and then quantified by ImageJ software. Data presented are expressed as mean ± SEM (𝑛 = 7), and experimental groups marked by different
letters represented significant differences between groups at 𝑃 < 0.05 (Kruskal-Wallis test followed by Dunn’s post hoc test). N + S: NAFLD +
SAMC cotreatment.
a few of them showed very positive outcomes [23]. We have
reported that administration of 200mg/kg SAMC during
the development of NAFLD in a rat model could attenuate
the histolopathogical changes, lipid metabolism dysfunction,
oxidative stress, and inflammation through kinase- and
transcription-factor-dependent pathways with minimal side
effects on healthy animals [20]. In the current study, we
demonstrated the antiapoptotic and proautophagic proper-
ties of SAMC cotreatment. During NAFLD development,
both intrinsic and extrinsic apoptotic pathways have been
activated to transduce death signals to the functional protein
caspase-3 under the actions of p53. As the upstream regu-
lating pathways, both LKB1/AMPK and PI3K/Akt pathways
were inhibited to further facilitate the process of apoptosis.
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Figure 4: Addition of SAMC attenuated extrinsic apoptotic pathway components during the development of NAFLD. Protein expression
of (a) Fas, (b) TRAIL, (c) FADD, and (d) cleaved caspase-8 were measured by Western blot and then quantified by ImageJ software. Data
presented are expressed as mean ± SEM (𝑛 = 7), and experimental groups marked by different letters represented significant differences
between groups at 𝑃 < 0.05 (Kruskal-Wallis test followed by Dunn’s post hoc test). N + S: NAFLD + SAMC cotreatment.
Addition of SAMC targeted both intrinsic and extrinsic
pathways through restoring the LKB1/AMPK and PI3K/Akt
pathways, leading to reduced caspase-3 activity and apoptosis
in the liver. In addition, treatment of SAMC further enhanced
the hepatic autophagy through the inhibition of mTOR,
contributing to the ameliorative effects of SAMC.
Apoptosis of liver cells and adipocytes is often found in
NAFLD patients and experimental animals [4, 24]. It is con-
sidered as a critical factor for the progression of NAFLD to
NASH [8]. Inhibition of excessive apoptosis in the liver may
be helpful in the treatment of NASH experimentally and clin-
ically. In response to cellular damage, such as hypoxia, DNA
damage, and fat accumulation, the p53 tumor suppressor is
activated to inhibit cell proliferation through promotion of
intrinsic and extrinsic apoptotic pathways [9]. Previous study
found that the extrinsic pathway of apoptosis (especially the
activation of Fas/FasL system) may be a central event for the
induction of apoptosis in NAFLD [7, 25]. Another report
also showed that the activation of p53 and TRAIL receptor
expression is associated with apoptosis in a methionine and
choline deficient (MCD) diet model [26].Therefore, it is very
clear that both intrinsic and extrinsic pathways of apoptosis
are activated in NAFLD despite the action of p53, which is
consistent with our current findings of clinically relevant and
not genetically modified NAFLD rat model [27]. Interest-
ingly, several previous reports demonstrated that in cancer
cell, addition of SAMC induced apoptosis by microtubule
depolymerization, JNK1, and caspase-3 activation [17, 28].
The discrepancy of results between these reports and our
current study may be due to different microenvironment.
In cancer cells, apoptosis is a beneficial event which can
retard the proliferation of tumor cells, whereas in NAFLD
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Figure 5: Addition of SAMC reduced NAFLD-induced hepatic apoptosis via modulating the LKB1/AMPK and PI3K/Akt pathways. Protein
expressions of phosphorylated and total (a) LKB1, (b) AMPK, (c) PI3 K, and (d) Akt were measured by Western blot and then quantified
by ImageJ software. Data presented are expressed as mean ± SEM (𝑛 = 7), and experimental groups marked by different letters represented
significant differences between groups at𝑃 < 0.05 (Kruskal-Wallis test followed byDunn’s post hoc test). N + S: NAFLD+ SAMC cotreatment.
rats, apoptosis is a detrimental event responsible for the
progression and severity of NAFLD. Therefore, SAMC may
exert distinct action on apoptosis under different circum-
stances, whichever is more beneficial to the host. Indeed,
the underlying mechanisms for this interesting phenomenon
require further investigations.
The detailed function and mechanism of autophagy
in NAFLD development are not fully elucidated. Recent
studies pointed out that autophagy may selectively target
lipid droplets within hepatocytes for degradation, leading to
reduction of steatosis. This process is called lipophagy [29].
Pharmacological inhibition of vps34 by 3-methyladenine
(3MA) increases the triglyceride (TG) contents in normal cell
or cell treated with unsaturated fatty acid. Inhibition of neg-
ative regulator of autophagy, mTOR, by rapamycin decreases
oleic acid-induced TG levels in cultured hepatocytes [29, 30]
and fatty liver mouse model [31]. Therefore, enhancing
autophagy is considered as a novel therapeutic strategy for
NAFLD therapy [32]. In this study, SAMC enhanced the
hepatic autophagy duringNAFLD development, with further
reduced activity of mTOR, indicating a mTOR-directed
pathway. Whether this process is directly related to the
reduction of lipid contents in hepatocytes needs future
investigations.
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Figure 6: Cotreatment with SAMC further enhanced hepatic autophagy through inhibition of mTOR activity. Protein expressions of (a)
phosphorylated and total mTOR, (b) vps34, (c) beclin 1, (d) Atg 12, (e) LC3 II and (f) p62 were measured byWestern blot and then quantified
by ImageJ software. Data presented are expressed as mean ± SEM (𝑛 = 7), and experimental groups marked by different letters represented
significant differences between groups at𝑃 < 0.05 (Kruskal-Wallis test followed byDunn’s post hoc test). N + S: NAFLD+ SAMC cotreatment.
To further investigate the upstream signaling regulators
of apoptosis and autophagy in the liver, we assessed the phos-
phorylation and total forms of LKB1/AMPK and PI3K/Akt
pathways and found that reactivation of these two pathways
contributed to the cell survival during NAFLD. AMPK is an
important enzyme response to energy deprivation and, in
some cases, cellular stress to induce apoptosis through the
AMPK-p53 axis [33]. During NAFLD, AMPK increases the
transport of FFAs into the mitochondria, as well as promotes
𝛽-oxidation, thus restoring energy balance [34]. In many
cases, activation of AMPK protected cells from apoptosis.
In an iron-induced hepatic oxidative stress and liver injury
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model, addition of sauchinone, a bioactive lignan, activated
the LKB1/AMPKpathway, resulting in inhibition of apoptosis
in the liver [35]. Moreover, an in vitro study using HepG2 cell
line found that resveratrol attenuates arachidonic acid and
iron-induced apoptosis through activation of LKB1/AMPK
pathway [36]. Recent study found that activation of hypotha-
lamic autophagy PI3 K/Akt pathway has also been found
to play an important role in the impairment of mitochon-
dria during NAFLD development. In a high-fat diet fed
NAFLD rat model, reduced phosphorylated form of PI3 K
and Akt and total form of PI3 K were observed with hepatic
apoptosis. Treatment of pharmacological inhibitors of PI3 K
or Akt instead of high-fat diet mimicked such phenomena
[37]. Thus, in this study, the modulation of the activity of
LKB1/AMPK and PI3K/Akt pathways by SAMC administra-
tion may partly be involved in its antiapoptotic effect during
NAFLD development. However, further investigations are
needed to clarify the interactions between these pathways and
p53, as well as the possible involvement of other apoptosis-
related signaling pathways. In addition, it is not clear whether
the antiapoptotic effects of SAMC on NAFLD are a direct
effect or a consequence of “upstream” antioxidant and anti-
inflammatory effects. Although some studies proposed the
regulatory roles of LKB1/AMPK and PI3K/Akt pathways
in autophagy [38], in this study, it is suggested that the
further enhancement of autophagy by SAMC cotreatment
was not through these two pathways. Detailed mechanisms
for distinct regulation of apoptosis and autophagy by SAMC
are waiting for further study.
In conclusion, our results clearly showed the antiapop-
totic and proautophagy properties of SAMCduring the devel-
opment of NAFLD in a rat model. The protective effect of
SAMC was partly through modulating both p53-dependent
intrinsic and extrinsic apoptotic pathways, as well as the
inhibition of mTOR activity. Restoration of LKB1/AMPK and
PI3K/Akt pathways also contributed to this protective effect
of SAMC.
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